Novo Seeks Injunction on Lilly Obesity Ads: The Comparative Claims Precedent

Novo isn't suing Lilly over obesity ads anymore. It's going to ask a judge to switch the campaign off.

And that's the fourth-biggest thing that happened today. Sanofi killed amlitelimab, Ipsen's Bylvay missed in biliary atresia, and CHMP cleared a pair of NewAmsterdam cholesterol drugs before most of the East Coast was awake. It's been a busy Friday. Let's get into it.

Welcome to The Pharma Closeout for Friday, July 24th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's take it apart.

Novo Nordisk is going for an injunction against Eli Lilly's obesity advertising. Fierce Pharma had the story out earlier this morning. Not damages, not a corrected footnote — a court order to stop running the ads.

Look at the sequence, because the sequence is the story. Novo sent a cease-and-desist. Lilly kept the campaign live. Novo sued, calling the ads deceptive and alleging Lilly claims its GLP-1 products are broadly superior. Lilly's reply was one word: truthful.

Nobody walks a letter up to an injunction bid unless they think they win.

Or unless they've decided the discovery is worth more than the ruling. But here's my issue with reading this as a legal story at all. Read it as a promotional-standards story and it changes shape. This lands the same week an advocacy group formally asked the FDA to ban direct-to-consumer prescription ads outright — that's STAT's reporting. Novo may win, Novo may lose. Either way there's now a public record of the two market leaders accusing each other of misleading patients while the agency is being asked to take the entire channel away.

That's a fair correction and I'll take it. The venue matters less than the exhibit list. If Lilly has to substantiate "broadly superior" in a filing, that substantiation becomes the reference document every medical-legal-regulatory committee in the industry reads next quarter.

Which is where the real cost sits. Neither company has to lose for this to be expensive. The moment comparative superiority in obesity gets litigated on the record, the claims budget for everything behind it gets repriced — Novo's, Lilly's, and every 2027 entrant whose differentiation story is built on beating one of them.

So the competitive read. If you're running commercial strategy in cardiometabolic and your launch plan leans on a head-to-head claim, pressure-test that claim now — before a judge does it for you. Meanwhile Lilly closed modestly higher on the day. The market is filing this under noise.

The market's probably right about the quarter and wrong about the decade. Watch what the court does with the injunction request. A judge willing to pull obesity ads off air creates something the FDA has never had to enforce this hard. That's the ruling. Not the damages.

Which brings us to the day's other casualty list — and it's a real one. Sanofi has discontinued all clinical development of amlitelimab in moderate-to-severe atopic dermatitis. RTTNews had it early this morning. We flagged the early version of this yesterday; today it's the full stop. Sanofi's language: overall efficacy and safety data generated to date do not support further development. Endpoints frames it as the Kymab-originated OX40L antibody — this asset came in with the Kymab acquisition.

The word doing the work in that sentence is safety. When a large-cap kills an immunology program on efficacy or portfolio grounds, the statement says efficacy and stops there. Naming safety in the same breath, in a discontinuation with no data attached, is not standard boilerplate. That's my read — and it's the sentence Amgen and Kyowa Kirin's team will read twice, because rocatinlimab now carries the class question by itself.

Second failure, same morning. Ipsen's Phase 3 BOLD trial — Bylvay versus placebo in biliary atresia — missed. Ipsen posted it overnight. We had the early read yesterday; the trial name and the placebo-controlled design are what's new.

Biliary atresia was always the hardest ask in that franchise. And a miss here doesn't touch the cholestatic pruritus business — but it does close the expansion story people were carrying in their models.

Third one is ours to settle. Back in March we said every additional retatrutide readout would either confirm or complicate Lilly's narrative. Today it does both: Lilly is moving to seek FDA approval in obesity with new data, per BioPharma Dive — and STAT's read is that the new data leaves open questions on cardiovascular benefit.

That's the whole analyst fight in one sentence. Filing on weight is the easy half. The heart-benefit question decides whether the triple agonist stacks on top of tirzepatide and orforglipron, or whether Lilly ends up running three assets at the same prescriber.

And a winner, for balance. Arrowhead's latest fat-lowering data was called a best-case scenario — safety plus effects on triglycerides and on pancreatitis cases — and analysts read it as competitive with the rival Ionis therapy. So the pipeline scoreboard today: one immunology asset dead, one rare-disease expansion closed, one cardiometabolic asset that just got harder to displace.

There's a second tier under all of that worth a fast pass.

Fast pass it is. Amgen submitted new analyses to the FDA this morning seeking a hearing to keep Tavneos on the market — and Mirador has already unveiled a Kira-derived drug aimed squarely at the gap. Merck struck voluntary licensing deals in poor countries for its experimental HIV prevention pill, and it's preparing expanded access to a monthly PrEP pill early. Chugai reported first-half earnings and revenue up on higher drug sales and reaffirmed annual guidance. And on the capital markets side, Scribe Therapeutics' listing was among the smallest of this year's biotech IPOs — and one of only two priced without a drug in Phase 2 or later.

That Scribe detail is the one I'd keep. A gene-editing company clearing a public listing on preclinical assets tells you the window isn't just open, it's open to earlier-stage stories than it was six months ago. Also on the wire: Endpoints has Biogen's Alzheimer's data spurring excitement and confusion about tau-targeting drugs in the same breath, European regulators moving to bolster clinical trial transparency, a fatal gene-editing trial in China raising real oversight questions, and rare-disease drugmakers seeking exemption from the Trump price-cut pilots.

Any one of those is a Tuesday lead on a slower week. Today they're footnotes — which tells you something about the week itself.

On the regulatory side, Europe is where the day actually turned. NewAmsterdam Pharma and Menarini received a positive CHMP opinion recommending marketing authorization for Ubeslo — obicetrapib monotherapy — and Evlarco, the obicetrapib plus ezetimibe fixed-dose combination. We've been tracking this committee calendar for some time now. It landed, and it landed on both products.

Both presentations changes Menarini's commercial architecture in Europe, not just its launch date. Monotherapy is the specialist entry point. The fixed-dose combination is the volume tier — and the reason a payer writes a broader protocol rather than a narrow one.

And it was a three-outcome CHMP day, which is the part worth flagging. Same committee recommended Minoryx's ALD drug and rejected Zevra's Meplyffa. Same room, same standard, three different answers — that's a committee applying evidence thresholds, not drifting with policy.

Also worth noting on the regulatory front, the peptide advisory committee we covered Tuesday finished its second day. How did it end?

Split, across both days — and that's not a technicality. Panelists narrowly backed broader use of certain peptides despite FDA staff concerns, which BioPharma Dive frames as a win for Robert F. Kennedy Junior's MAHA agenda. STAT has the panel narrowly rejecting compounding of one peptide and backing two others. Fierce named the failure: emideltide didn't make the grade. But the thread I said to watch on Tuesday is still open. Committees advise. Whether agency leadership adopts a position its own scientific staff argued against — that's the actual decision, and it hasn't been made.

And the tariff line moved again. Trump's threatened levies of up to 200 percent on imported generics are the escalation we flagged Wednesday. BioPharma Dive's framing is the one that matters: branded tariff threats barely moved revenue, generics could be genuinely disruptive.

Put the three together and you can see the shape of this agency right now. A committee overruling its own reviewers. A marketed drug fighting for its label. And a tariff threat pointed at the cheapest link in the supply chain. If your regulatory strategy this year rests on precedent — precedent is the variable.

Looking ahead. Obicetrapib's next gate is the European Commission decision that follows a positive opinion — no timing disclosed, but that's what sets launch economics. Watch whether the FDA grants Amgen the Tavneos hearing it asked for today. And Arrowhead's fiscal third-quarter call is coming up soon, the first time management has to talk about that fat-lowering data with a competitive question in the room.

I'd put Biogen on the list too. Confusion inside a drug class at this stage usually means the next dataset writes the frame for everybody — so whoever reads out next on tau sets the terms.

And the one that resolves nothing today and changes a lot if it lands: the injunction request on Lilly's ads. Watch the docket, not the press releases — the filings will tell you what each side actually believes it can prove.

And that is your Pharma Closeout for Friday, July 24th — Novo taking Lilly's ad campaign to a judge, Sanofi ending amlitelimab, Ipsen's BOLD miss, CHMP clearing obicetrapib on both presentations, and a peptide panel that split its own votes. That's a dense week by any standard, and next week has Arrowhead and a docket in it. If someone on your team needs to be across this week in pharma, send them the feed — and if this briefing saves you time, follow us on Spotify and drop a rating.

Go enjoy your weekend. We'll be back Sunday with the Weekend Closeout. See you then!